参考文献
[1] Toba A, Kariya T, Aoyama R, et al. Impact of age on left ventricular geometry and diastolic function in elderly patients with treated hypertension[J]. Blood Press, 2017,26(5):264-271. DOI: 10.1080/08037051.2017.1306422.
[2] Avelar E, Cloward TV, Walker JM, et al. Left ventricular hypertrophy in severe obesity: interactions among blood pressure, nocturnal hypoxemia, and body mass[J]. Hypertension, 2007,49(1):34-39. DOI: 10.1161/01.HYP.0000251711.92482.14.
[3] Diamond JA, Phillips RA. Hypertensive heart disease[J]. Hypertens Res, 2005,28(3):191-202. DOI: 10.1291/hypres.28.191.
[4] Yang Y, Zhang N, Huang W, et al. The relationship of alcohol consumption with left ventricular mass in people 35 years old or older in rural areas of Western China[J]. J Am Soc Hypertens, 2017,11(4):220-226. DOI: 10.1016/j.jash.2017.02.002.
[5] Le Corvoisier P, Adamy C, Sambin L, et al. The cardiac reninangiotensin system is responsible for high-salt diet-induced leftventricular hypertrophy in mice[J]. Eur J Heart Fail, 2010,12(11):1171-1178. DOI: 10.1093/eurjhf/hfq146.
[6] Wang SX, Xue H, Zou YB, et al. Prevalence and risk factors for left ventricular hypertrophy and left ventricular geometric abnormality in the patients with hypertension among Han Chinese[J]. Chin Med J (Engl), 2012,125(1):21-26.
[7] Devereux RB. Therapeutic options in minimizing left ventricular hypertrophy[J]. Am Heart J, 2000,139(1 Pt 2):S9-14. DOI: 10.1067/mhj.2000.102902.
[8] Bang CN, Soliman EZ, Simpson LM, et al. Electrocardiographic left ventricular hypertrophy predicts cardiovascular morbidity and mortality in hypertensive patients: the ALLHAT study[J]. Am J Hypertens, 2017,30(9):914-922. DOI: 10.1093/ajh/hpx067.
[9] Yasuno S, Ueshima K, Oba K, et al. Clinical significance of left ventricular hypertrophy and changes in left ventricular mass in high-risk hypertensive patients: a subanalysis of the Candesartan Antihypertensive Survival Evaluation in Japan trial[J]. J Hypertens, 2009,27(8):1705-1712. DOI: 10.1097/HJH.0b013e32832c6968.
[10] Bang CN , Devereux RB , Okin PM . Regression of electrocardiographic left ventricular hypertrophy or strain is associated with lower incidence of cardiovascular morbidity and mortality in hypertensive patients independent of blood pressure reduction - A LIFE review[J]. J Electrocardiol, 2014,47(5):630-635. DOI: 10.1016/j.jelectrocard.2014.07.003.
[11] Sokolow M, Lyon TP. The ventricular complex in left ventricular hypertrophy as obtained by unipolar precordial and limb leads. 1949[J]. Ann Noninvasive Electrocardiol, 2001,6(4):343-368.
[12] Schillaci G, Battista F, Pucci G. A review of the role of electrocardiography in the diagnosis of left ventricular hypertrophy in hypertension[J]. J Electrocardiol, 2012,45(6):617-623. DOI:10.1016/j.jelectrocard.2012.08.051.
[13] 施仲伟 , 龚兰生 , 胡厚达 , 等 . 左心室肥大心电图诊断标准的超声心动图对照评价 [J]. 上海医学 ,1987(9):504-506.
[14] Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH)[J].G Ital Cardiol (Rome), 2018,19(11):3-73. DOI: 10.1714/3026.30245.
[15] 中国高血压防治指南修订委员会 , 高血压联盟 ( 中国 ) 中华医学会心血管病学分会 , 中国医师协会高血压专业委员会 , 等 . 中国高血压防治指南 (2018 年修订版 )[J]. 中国心血管杂志 ,2019,24(1):24-56. DOI: 10.3969/j.issn.1007-5410.2019.01.002.
[16] Angeli F, Verdecchia P, Cavallini C, et al. Electrocardiography for diagnosis of left ventricular hypertrophy in hypertensive patients with atrial fibrillation[J]. Int J Cardiol Hypertens,2019,1:100004.DOI:10.1061/j.ijchy.2019.100004.
[17] Hancock EW, Deal BJ, Mirvis DM, et al. AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram: part V: electrocardiogram changes associated with cardiac chamber hypertrophy: a scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society. Endorsed by the International Society for Computerized Electrocardiology[J]. J Am Coll Cardiol, 2009,53(11):992-1002. DOI: 10.1016/j.jacc.2008.12.015.
[18] 刘延玲 , 李靖 , 王剑鹏 , 等 . 超声心动图评价正常心脏结构与功能 [J]. 中华超声影像学杂志,2006,15(1):13-16. DOI: 10.3760/j.issn:1004-4477.2006.01.004.
[19] Yao GH, Deng Y, Liu Y, et al. Echocardiographic measurements in normal chinese adults focusing on cardiac chambers and great arteries: a prospective, nationwide, and multicenter study[J]. J Am Soc Echocardiogr, 2015,28(5):570-579. DOI: 10.1016/j.echo.2015.01.022.
[20] Klingbeil AU, Schneider M, Martus P, et al. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension[J]. Am J Med, 2003,115(1):41-46. DOI: 10.1016/s0002-9343(03)00158-x.
[21] Cuspidi C, Muiesan ML, Valagussa L, et al. Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: the candesartan assessment in the treatment of cardiac hypertrophy (CATCH) study[J]. J Hypertens,2002,20(11):2293-2300. DOI:10.1097/00004872-200211000-00030.
[22] Barrios V, Escobar C, Calderón A, et al. Regression of left ventricular hypertrophy by a candesartan-based regimen in clinical practice. The VIPE study[J]. J Renin Angiotensin Aldosterone Syst, 2006,7(4):236-242. DOI: 10.3317/jraas.2006.044.
[23] Ogihara T, Fujimoto A, Nakao K, et al. ARB candesartan and CCB amlodipine in hypertensive patients: the CASE-J trial[J]. Expert Rev Cardiovasc Ther, 2008,6(9):1195-1201. DOI: 10.1586/14779072.6.9.1195.
[24] Devereux RB, Dahlöf B, Gerdts E, et al. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial[J]. Circulation, 2004,110(11):1456-1462. DOI: 10.1161/01.CIR.0000141573.44737.5A.
[25] Lacourcière Y, Asmar R. A comparison of the efficacy and duration of action of candesartan cilexetil and losartan as assessed by clinic and ambulatory blood pressure after a missed dose, in truly hypertensive patients: a placebo-controlled, forced titration study. Candesartan/Losartan study investigators[J]. Am J Hypertens, 1999,12(12 Pt 1-2):1181-1187. DOI: 10.1016/s0895-7061(99)00142-9.
[26] Gradman AH. AT(1)-receptor blockers: differences that matter[J]. J Hum Hypertens, 2002,16 Suppl 3:S9-S16. DOI: 10.1038/sj.jhh.1001434.
[27] Eklind-Cervenka M, Benson L, Dahlström U, et al. Association of candesartan vs losartan with all-cause mortality in patients with heart failure[J]. JAMA, 2011,305(2):175-182. DOI: 10.1001/jama.2010.1949.